GOSS vs MNKD vs UTHR vs NKTR vs IQV

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus -57. 7% for Gossamer Bio, Inc. (GOSS). United Therapeutics Corporation (UTHR) offers the better valuation at 19. 6x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Gossamer Bio, Inc. (GOSS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, United Therapeutics Corporation (UTHR) is the cheapest at 19.

6x versus MannKind Corporation at 183. 0x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus United Therapeutics Corporation's 1. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, United Therapeutics Corporation (UTHR) delivered a total return of +203.

9%, compared to -98. 2% for Gossamer Bio, Inc. (GOSS). Over 10 years, the gap is even starker: UTHR returned +396. 1% versus GOSS's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), United Therapeutics Corporation (UTHR) is the lower-risk stock at 0.

14β versus Gossamer Bio, Inc. 's 2. 45β — meaning GOSS is approximately 1707% more volatile than UTHR relative to the S&P 500. On balance sheet safety, Nektar Therapeutics (NKTR) carries a lower debt/equity ratio of 166% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus -57. 7% for Gossamer Bio, Inc. (GOSS). On earnings-per-share growth, the picture is similar: United Therapeutics Corporation grew EPS 13. 1% year-over-year, compared to -200. 0% for Gossamer Bio, Inc.. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.

9% net margin versus -351. 5% for Gossamer Bio, Inc. — meaning it keeps 41. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 47. 7% versus -336. 8% for GOSS. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus United Therapeutics Corporation's 1. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 2x forward P/E versus 19. 2x for United Therapeutics Corporation — 5. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GOSS: 373. 6% to $0. 77.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, United Therapeutics Corporation (UTHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

14), +396. 1% 10Y return). Gossamer Bio, Inc. (GOSS) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTHR: +396. 1%, GOSS: -99. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GOSS is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock; UTHR is a mid-cap quality compounder stock; NKTR is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.